OBJECTIVES: As increasing numbers of patients are being treated with outpatient parenteral antimicrobial therapy (OPAT), it becomes ever more important to ascertain the risks and benefits of such treatment for patients. METHODS: We conducted a retrospective analysis of 1,515 patients with methicillin-sensitive Staphylococcus aureus infections who were treated with outpatient parenteral antimicrobial monotherapy. All patients were included in the adverse drug reaction analysis; 1,252 were evaluable for purposes of evaluating treatment efficacy. RESULTS: The six antibiotics most frequently used in this study (ceftriaxone, cefazolin, vancomycin, oxacillin, nafcillin, and clindamycin) appeared to be equivalent in achieving the desired efficacy outcome. CONCLUSIONS: Vancomycin was associated with a significantly greater number of side effects than was ceftriaxone, cefazolin, or oxacillin, and nafcillin was associated with a significantly greater number of adverse events than ceftriaxone.
OBJECTIVES: As increasing numbers of patients are being treated with outpatient parenteral antimicrobial therapy (OPAT), it becomes ever more important to ascertain the risks and benefits of such treatment for patients. METHODS: We conducted a retrospective analysis of 1,515 patients with methicillin-sensitive Staphylococcus aureus infections who were treated with outpatient parenteral antimicrobial monotherapy. All patients were included in the adverse drug reaction analysis; 1,252 were evaluable for purposes of evaluating treatment efficacy. RESULTS: The six antibiotics most frequently used in this study (ceftriaxone, cefazolin, vancomycin, oxacillin, nafcillin, and clindamycin) appeared to be equivalent in achieving the desired efficacy outcome. CONCLUSIONS:Vancomycin was associated with a significantly greater number of side effects than was ceftriaxone, cefazolin, or oxacillin, and nafcillin was associated with a significantly greater number of adverse events than ceftriaxone.
Authors: Brent W Wieland; Jodie R Marcantoni; Kerry M Bommarito; David K Warren; Jonas Marschall Journal: Clin Infect Dis Date: 2011-12-05 Impact factor: 9.079
Authors: Kimberly G Blumenthal; Ilan Youngster; Erica S Shenoy; Aleena Banerji; Sandra B Nelson Journal: Antimicrob Agents Chemother Date: 2014-03-17 Impact factor: 5.191
Authors: Jasmit S Minhas; Paige G Wickner; Aidan A Long; Aleena Banerji; Kimberly G Blumenthal Journal: Ann Allergy Asthma Immunol Date: 2016-05-04 Impact factor: 6.347
Authors: Ursula C Patel; Erin L McKissic; Douglas Kasper; Joseph R Lentino; Constance T Pachucki; Todd Lee; Bert K Lopansri Journal: Int J Clin Pharm Date: 2014-09-04
Authors: J Alexander Viehman; Louise-Marie Oleksiuk; Kathleen R Sheridan; Karin E Byers; Peimei He; Bonnie A Falcione; Ryan K Shields Journal: Antimicrob Agents Chemother Date: 2016-04-22 Impact factor: 5.191